Skip Header

You are using a version of Internet Explorer that may not display all features of this website. Please upgrade to a modern browser.
Contribute Send feedback
Read comments (?) or add your own

P10635 (CP2D6_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Last modified April 16, 2014. Version 158. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (6) | Third-party data text xml rdf/xml gff fasta
to top of pageNames·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order

Names and origin

Protein namesRecommended name:
Cytochrome P450 2D6

EC=1.14.14.1
Alternative name(s):
CYPIID6
Cytochrome P450-DB1
Debrisoquine 4-hydroxylase
Gene names
Name:CYP2D6
Synonyms:CYP2DL1
OrganismHomo sapiens (Human) [Reference proteome]
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length497 AA.
Sequence statusComplete.
Protein existenceEvidence at protein level

General annotation (Comments)

Function

Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants. Ref.9

Catalytic activity

RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O.

Cofactor

Heme group.

Subcellular location

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.

Induction

By pregnancy.

Polymorphism

Genetic variations in CYP2D6 are the cause of poor drug metabolism CYP2D6-related [MIM:608902]. The CYP2D6 gene is highly polymorphic. CYP2D6 activity ranges widely within a population comprising ultrarapid (UM), extensive (EM), intermediate (IM) and poor (PM) metabolizer phenotypes. UM and PM are those most at risk for treatment failure or dose-dependent drug toxicity, respectively. Of the Caucasian populations of Europe and North America, 5%-10% are of the PM phenotype and are unable to metabolize the antihypersensitive drug debrisoquine and numerous other drugs.

Allele CYP2D6*7 was also known as CYP2D6E, allele CYP2D6*9 as CYP2D6C, allele CYP2D6*10 as CYP2D6J, allele CYP2D6*17 as CYP2D6Z.

Isozymes CYP2D6.45 (Lys-155, Cys-296 and Thr-486) and CYP2D6.46 (His-26, Lys-155, Cys-296 and Thr-486) are functional.

Sequence similarities

Belongs to the cytochrome P450 family.

Ontologies

Keywords
   Cellular componentEndoplasmic reticulum
Membrane
Microsome
   Coding sequence diversityAlternative splicing
Polymorphism
   LigandHeme
Iron
Metal-binding
   Molecular functionMonooxygenase
Oxidoreductase
   Technical term3D-structure
Complete proteome
Reference proteome
Gene Ontology (GO)
   Biological_processalkaloid catabolic process

Inferred from direct assay PubMed 15039299. Source: BHF-UCL

alkaloid metabolic process

Inferred from direct assay PubMed 19651758. Source: BHF-UCL

coumarin metabolic process

Inferred from direct assay PubMed 19438707. Source: BHF-UCL

drug catabolic process

Inferred from direct assay PubMed 15039299. Source: BHF-UCL

drug metabolic process

Inferred from direct assay PubMed 19219744. Source: BHF-UCL

heterocycle metabolic process

Inferred from direct assay PubMed 15327587PubMed 19651758. Source: BHF-UCL

isoquinoline alkaloid metabolic process

Inferred from direct assay PubMed 19448135. Source: BHF-UCL

monoterpenoid metabolic process

Inferred from direct assay PubMed 16401082. Source: BHF-UCL

negative regulation of binding

Inferred from direct assay PubMed 19448135. Source: BHF-UCL

negative regulation of cellular organofluorine metabolic process

Inferred from direct assay PubMed 19448135. Source: BHF-UCL

oxidation-reduction process

Inferred from direct assay PubMed 16401082PubMed 19219744. Source: BHF-UCL

oxidative demethylation

Inferred from direct assay PubMed 15039299PubMed 19438707. Source: BHF-UCL

small molecule metabolic process

Traceable author statement. Source: Reactome

steroid metabolic process

Inferred from mutant phenotype PubMed 18356043. Source: BHF-UCL

xenobiotic metabolic process

Traceable author statement PubMed 19438707. Source: BHF-UCL

   Cellular_componentendoplasmic reticulum

Traceable author statement PubMed 19438707. Source: BHF-UCL

endoplasmic reticulum membrane

Traceable author statement. Source: Reactome

mitochondrion

Inferred from direct assay PubMed 19438707. Source: BHF-UCL

   Molecular_functionaromatase activity

Inferred from electronic annotation. Source: UniProtKB-EC

drug binding

Inferred from direct assay PubMed 19448135. Source: BHF-UCL

heme binding

Inferred from direct assay Ref.9. Source: UniProtKB

iron ion binding

Inferred from electronic annotation. Source: InterPro

monooxygenase activity

Inferred from direct assay PubMed 15327587PubMed 19651758. Source: BHF-UCL

oxidoreductase activity

Inferred from direct assay PubMed 15039299PubMed 16401082PubMed 19219744. Source: BHF-UCL

Complete GO annotation...

Alternative products

This entry describes 2 isoforms produced by alternative splicing. [Align] [Select]
Isoform 1 (identifier: P10635-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
Isoform 2 (identifier: P10635-2)

The sequence of this isoform differs from the canonical sequence as follows:
     118-168: Missing.
Note: No experimental confirmation available.

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 497497Cytochrome P450 2D6
PRO_0000051731

Sites

Metal binding4431Iron (heme axial ligand)
Binding site3011Substrate Probable

Natural variations

Alternative sequence118 – 16851Missing in isoform 2.
VSP_044486
Natural variant111V → M in allele CYP2D6*35. Ref.18
Corresponds to variant rs769258 [ dbSNP | Ensembl ].
VAR_008366
Natural variant261R → H in allele CYP2D6*21 and allele CYP2D6*46. Ref.4 Ref.6 Ref.18
Corresponds to variant rs28371696 [ dbSNP | Ensembl ].
VAR_008367
Natural variant281R → C in allele CYP2D6*22.
VAR_008368
Natural variant341P → S in allele CYP2D6*10 and allele CYP2D6*14; poor debrisquone metabolism. Ref.11 Ref.18
Corresponds to variant rs1065852 [ dbSNP | Ensembl ].
VAR_008336
Natural variant421G → R in allele CYP2D6*12; impaired metabolism of sparteine. Ref.15
Corresponds to variant rs5030862 [ dbSNP | Ensembl ].
VAR_001256
Natural variant851A → V in allele CYP2D6*23.
VAR_008369
Natural variant911L → M. Ref.18
Corresponds to variant rs28371703 [ dbSNP | Ensembl ].
VAR_024720
Natural variant941H → R. Ref.18
Corresponds to variant rs28371704 [ dbSNP | Ensembl ].
VAR_024721
Natural variant1071T → I in allele CYP2D6*17; poor debrisquone metabolism. Ref.14 Ref.18
Corresponds to variant rs28371706 [ dbSNP | Ensembl ].
VAR_008337
Natural variant1201F → I. Ref.18
Corresponds to variant rs1135822 [ dbSNP | Ensembl ].
VAR_024722
Natural variant1551E → K in allele CYP2D6*45A, allele CYP2D6*45B and allele CYP2D6*46. Ref.4 Ref.18
Corresponds to variant rs28371710 [ dbSNP | Ensembl ].
VAR_024723
Natural variant1691G → R in allele CYP2D6*14; poor debrisquone metabolism. Ref.17
VAR_008338
Natural variant2121G → E in allele CYP2D6*6B and allele CYP2D6*6C. Ref.13
Corresponds to variant rs5030866 [ dbSNP | Ensembl ].
VAR_008339
Natural variant2311L → P.
Corresponds to variant rs17002853 [ dbSNP | Ensembl ].
VAR_045679
Natural variant2371A → S in allele CYP2D6*33. Ref.18
Corresponds to variant rs28371717 [ dbSNP | Ensembl ].
VAR_008370
Natural variant2811Missing in allele CYP2D6*9. Ref.10
VAR_008347
Natural variant2961R → C in allele CYP2D6*2, allele CYP2D6*12, allele CYP2D6*14, allele CYP2D6*17, allele CYP2D6*45A, allele CYP2D6*45B and allele CYP2D6*46. Ref.4 Ref.7 Ref.8 Ref.18
Corresponds to variant rs16947 [ dbSNP | Ensembl ].
VAR_008340
Natural variant2971I → L in allele CYP2D6*24.
VAR_008371
Natural variant3001A → G.
Corresponds to variant rs1058170 [ dbSNP | Ensembl ].
VAR_045680
Natural variant3111S → L.
Corresponds to variant rs1800754 [ dbSNP | Ensembl ].
VAR_014633
Natural variant3241H → P in allele CYP2D6*7; loss of activity. Ref.12
Corresponds to variant rs5030867 [ dbSNP | Ensembl ].
VAR_008348
Natural variant3291R → L.
Corresponds to variant rs3915951 [ dbSNP | Ensembl ].
VAR_059150
Natural variant3431R → G in allele CYP2D6*25.
VAR_008372
Natural variant3651R → H.
Corresponds to variant rs1058172 [ dbSNP | Ensembl ].
VAR_045681
Natural variant3691I → T in allele CYP2D6*26.
VAR_008373
Natural variant3731G → S.
Corresponds to variant rs2856959 [ dbSNP | Ensembl ].
VAR_059151
Natural variant4101E → K in allele CYP2D6*27.
VAR_008374
Natural variant4181E → K. Ref.18
VAR_024724
Natural variant4691P → A. Ref.18
Corresponds to variant rs1135833 [ dbSNP | Ensembl ].
VAR_024725
Natural variant4781H → Y. Ref.18
Corresponds to variant rs28371735 [ dbSNP | Ensembl ].
VAR_024726
Natural variant4861S → T in allele CYP2D6*2, allele CYP2D6*10, allele CYP2D6*12, allele CYP2D6*14, allele CYP2D6*17, allele CYP2D6*45A, allele CYP2D6*45B and allele CYP2D6*46; impaired metabolism of sparteine. Ref.4 Ref.7 Ref.8 Ref.11 Ref.18
Corresponds to variant rs1135840 [ dbSNP | Ensembl ].
VAR_008341

Experimental info

Sequence conflict3741V → M in AAA52153. Ref.1
Sequence conflict3741V → M in CAA30807. Ref.2

Secondary structure

......................................................................... 497
Helix Strand Turn

Details...

Sequences

Sequence LengthMass (Da)Tools
Isoform 1 [UniParc].

Last modified December 20, 2005. Version 2.
Checksum: 542B1D505DF3CDAC

FASTA49755,769
        10         20         30         40         50         60 
MGLEALVPLA VIVAIFLLLV DLMHRRQRWA ARYPPGPLPL PGLGNLLHVD FQNTPYCFDQ 

        70         80         90        100        110        120 
LRRRFGDVFS LQLAWTPVVV LNGLAAVREA LVTHGEDTAD RPPVPITQIL GFGPRSQGVF 

       130        140        150        160        170        180 
LARYGPAWRE QRRFSVSTLR NLGLGKKSLE QWVTEEAACL CAAFANHSGR PFRPNGLLDK 

       190        200        210        220        230        240 
AVSNVIASLT CGRRFEYDDP RFLRLLDLAQ EGLKEESGFL REVLNAVPVL LHIPALAGKV 

       250        260        270        280        290        300 
LRFQKAFLTQ LDELLTEHRM TWDPAQPPRD LTEAFLAEME KAKGNPESSF NDENLRIVVA 

       310        320        330        340        350        360 
DLFSAGMVTT STTLAWGLLL MILHPDVQRR VQQEIDDVIG QVRRPEMGDQ AHMPYTTAVI 

       370        380        390        400        410        420 
HEVQRFGDIV PLGVTHMTSR DIEVQGFRIP KGTTLITNLS SVLKDEAVWE KPFRFHPEHF 

       430        440        450        460        470        480 
LDAQGHFVKP EAFLPFSAGR RACLGEPLAR MELFLFFTSL LQHFSFSVPT GQPRPSHHGV 

       490 
FAFLVSPSPY ELCAVPR 

« Hide

Isoform 2 [UniParc].

Checksum: D1FB49C5A4B10965
Show »

FASTA44650,061

References

« Hide 'large scale' references
[1]"Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22."
Gonzalez F.J., Vilbois F., Hardwick J.P., McBride O.W., Nebert D.W., Gelboin H.V., Meyer U.A.
Genomics 2:174-179(1988) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
[2]"Characterization of the common genetic defect in humans deficient in debrisoquine metabolism."
Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P., Meyer U.A.
Nature 331:442-446(1988) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
Tissue: Liver.
[3]"The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene."
Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzalez F.J.
Am. J. Hum. Genet. 45:889-904(1989) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
[4]"Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans."
Gaedigk A., Bhathena A., Ndjountche L., Pearce R.E., Abdel-Rahman S.M., Alander S.W., Bradford L.D., Rogan P.K., Leeder J.S.
Pharmacogenomics J. 5:173-182(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CYP2D6*1), IDENTIFICATION OF ALLELES CYP2D6*41B; CYP2D6*45A; CYP2D6*45B AND CYP2D6*46, VARIANTS HIS-26; LYS-155; CYS-296 AND THR-486, CHARACTERIZATION OF ISOZYMES CYP2D6.45 AND CYP2D6.46.
[5]Erratum
Gaedigk A., Bhathena A., Ndjountche L., Pearce R.E., Abdel-Rahman S.M., Alander S.W., Bradford L.D., Rogan P.K., Leeder J.S.
Pharmacogenomics J. 5:276-276(2005)
[6]"CYP2D6 evolution and allele diversity among human races."
Koch W.H., Nikoloff D.M., Lu W., Pan R.M., deLeon J., Wedlund P.J.
Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT HIS-26.
[7]"The DNA sequence of human chromosome 22."
Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M. expand/collapse author list , Buck D., Burgess J., Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., Wright H.
Nature 402:489-495(1999) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], VARIANTS CYS-296 AND THR-486.
[8]"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), VARIANTS CYS-296 AND THR-486.
[9]"Crystal structure of human cytochrome P450 2D6."
Rowland P., Blaney F.E., Smyth M.G., Jones J.J., Leydon V.R., Oxbrow A.K., Lewis C.J., Tennant M.G., Modi S., Eggleston D.S., Chenery R.J., Bridges A.M.
J. Biol. Chem. 281:7614-7622(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 34-497 IN COMPLEX WITH HEME, FUNCTION.
[10]"Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype."
Tyndale R., Aoyama T., Broly F., Matsunaga T., Inaba T., Kalow W., Gelboin H.V., Meyer U.A., Gonzalez F.J.
Pharmacogenetics 1:26-32(1991) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*9 LYS-281 DEL.
[11]"Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism."
Yokota H., Tamura S., Furuya H., Kimura S., Watanabe M., Kanazawa I., Kondo I., Gonzalez F.J.
Pharmacogenetics 3:256-263(1993) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS CYP2D6*10 SER-34 AND THR-486.
[12]"A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine."
Evert B., Griese E.U., Eichelbaum M.
Naunyn Schmiedebergs Arch. Pharmacol. 350:434-439(1994) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*7 PRO-324.
[13]"An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution."
Daly A.K., Leathart J.B., London S.J., Idle J.R.
Hum. Genet. 95:337-341(1995) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*6B/6C GLU-212.
[14]"A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity."
Masimirembwa C., Persson I., Bertilsson L., Hasler J., Ingelman-Sundberg M.
Br. J. Clin. Pharmacol. 42:713-719(1996) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*17 ILE-107.
[15]"An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine."
Marez D., Legrand M., Sabbagh N., Lo-Guidice J.-M., Boone P., Broly F.
Hum. Genet. 97:668-670(1996) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*12 ARG-42.
[16]"Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution."
Marez D., Legrand M., Sabbagh N., Guidice J.M., Spire C., Lafitte J.J., Meyer U.A., Broly F.
Pharmacogenetics 7:193-202(1997) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS.
[17]"G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese."
Wang S.L., Lai M.D., Huang J.D.
Drug Metab. Dispos. 27:385-388(1999) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT CYP2D6*14 ARG-169.
[18]"Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population."
Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q., McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P.
Pharmacogenomics 5:895-931(2004) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS MET-11; HIS-26; SER-34; MET-91; ARG-94; ILE-107; ILE-120; LYS-155; SER-237; CYS-296; LYS-418; ALA-469; TYR-478 AND THR-486.
+Additional computationally mapped references.

Web resources

Cross-references

Sequence databases

EMBL
GenBank
DDBJ
M20403 mRNA. Translation: AAA52153.1.
X08006 mRNA. Translation: CAA30807.1.
M33388 Genomic DNA. Translation: AAA53500.1.
AY545216 Genomic DNA. Translation: AAS55001.1.
DQ282144 Genomic DNA. Translation: ABB77895.1.
DQ282145 Genomic DNA. Translation: ABB77896.1.
DQ282146 Genomic DNA. Translation: ABB77897.1.
DQ282151 Genomic DNA. Translation: ABB77899.1.
DQ282154 Genomic DNA. Translation: ABB77902.1.
DQ282155 Genomic DNA. Translation: ABB77903.1.
BX247885 Genomic DNA. Translation: CAP58857.1.
BC066877 mRNA. Translation: AAH66877.1.
BC075023 mRNA. Translation: AAH75023.1.
BC075024 mRNA. Translation: AAH75024.1.
PIRO4HUD1. S01199.
RefSeqNP_000097.3. NM_000106.5.
NP_001020332.2. NM_001025161.2.
UniGeneHs.333497.
Hs.648256.

3D structure databases

PDBe
RCSB PDB
PDBj
EntryMethodResolution (Å)ChainPositionsPDBsum
2F9QX-ray3.00A/B/C/D34-497[»]
3QM4X-ray2.85A/B34-497[»]
3TBGX-ray2.10A/B/C/D34-497[»]
3TDAX-ray2.67A/B/C/D34-497[»]
ProteinModelPortalP10635.
SMRP10635. Positions 48-497.
ModBaseSearch...
MobiDBSearch...

Protein-protein interaction databases

STRING9606.ENSP00000353820.

Chemistry

BindingDBP10635.
ChEMBLCHEMBL289.
DrugBankDB01193. Acebutolol.
DB00918. Almotriptan.
DB00866. Alprenolol.
DB01118. Amiodarone.
DB00321. Amitriptyline.
DB00613. Amodiaquine.
DB00182. Amphetamine.
DB01274. Arformoterol.
DB01238. Aripiprazole.
DB00335. Atenolol.
DB00289. Atomoxetine.
DB00972. Azelastine.
DB00612. Bisoprolol.
DB00921. Buprenorphine.
DB01156. Bupropion.
DB01197. Captopril.
DB00521. Carteolol.
DB01136. Carvedilol.
DB00482. Celecoxib.
DB00185. Cevimeline.
DB01114. Chlorpheniramine.
DB00477. Chlorpromazine.
DB00672. Chlorpropamide.
DB00356. Chlorzoxazone.
DB01410. Ciclesonide.
DB00501. Cimetidine.
DB01012. Cinacalcet.
DB00215. Citalopram.
DB01242. Clomipramine.
DB00575. Clonidine.
DB00257. Clotrimazole.
DB00363. Clozapine.
DB00318. Codeine.
DB00496. Darifenacin.
DB04840. Debrisoquin.
DB00705. Delavirdine.
DB01151. Desipramine.
DB00967. Desloratadine.
DB01191. Dexfenfluramine.
DB01576. Dextroamphetamine.
DB00514. Dextromethorphan.
DB00527. Dibucaine.
DB00586. Diclofenac.
DB00343. Diltiazem.
DB01075. Diphenhydramine.
DB00757. Dolasetron.
DB00843. Donepezil.
DB01142. Doxepin.
DB00476. Duloxetine.
DB01228. Encainide.
DB01175. Escitalopram.
DB00736. Esomeprazole.
DB00574. Fenfluramine.
DB01195. Flecainide.
DB00623. Fluphenazine.
DB00176. Fluvoxamine.
DB00983. Formoterol.
DB00674. Galantamine.
DB00317. Gefitinib.
DB01218. Halofantrine.
DB00502. Haloperidol.
DB00956. Hydrocodone.
DB00327. Hydromorphone.
DB00557. Hydroxyzine.
DB00458. Imipramine.
DB00332. Ipratropium.
DB01167. Itraconazole.
DB01026. Ketoconazole.
DB01210. Levobunolol.
DB00281. Lidocaine.
DB00455. Loratadine.
DB00934. Maprotiline.
DB00454. Meperidine.
DB00532. Mephenytoin.
DB01071. Mequitazine.
DB00933. Mesoridazine.
DB01403. Methotrimeprazine.
DB01233. Metoclopramide.
DB00264. Metoprolol.
DB00379. Mexiletine.
DB06148. Mianserin.
DB01110. Miconazole.
DB00683. Midazolam.
DB00805. Minaprine.
DB00370. Mirtazapine.
DB01171. Moclobemide.
DB00295. Morphine.
DB01149. Nefazodone.
DB00622. Nicardipine.
DB00699. Nicergoline.
DB01115. Nifedipine.
DB00540. Nortriptyline.
DB00904. Ondansetron.
DB00497. Oxycodone.
DB01192. Oxymorphone.
DB01267. Paliperidone.
DB00377. Palonosetron.
DB00715. Paroxetine.
DB01074. Perhexiline.
DB00850. Perphenazine.
DB00914. Phenformin.
DB00830. Phenmetrazine.
DB00960. Pindolol.
DB01035. Procainamide.
DB00433. Prochlorperazine.
DB01131. Proguanil.
DB01069. Promethazine.
DB01182. Propafenone.
DB00647. Propoxyphene.
DB00571. Propranolol.
DB01224. Quetiapine.
DB00908. Quinidine.
DB00468. Quinine.
DB00863. Ranitidine.
DB00243. Ranolazine.
DB00234. Reboxetine.
DB00734. Risperidone.
DB00503. Ritonavir.
DB01037. Selegiline.
DB06144. Sertindole.
DB01104. Sertraline.
DB00675. Tamoxifen.
DB00857. Terbinafine.
DB00342. Terfenadine.
DB00679. Thioridazine.
DB00373. Timolol.
DB01409. Tiotropium.
DB01124. Tolbutamide.
DB01036. Tolterodine.
DB00193. Tramadol.
DB00752. Tranylcypromine.
DB00656. Trazodone.
DB00726. Trimipramine.
DB00285. Venlafaxine.
DB01624. Zuclopenthixol.

PTM databases

PhosphoSiteP10635.

Polymorphism databases

DMDM84028191.

Proteomic databases

PaxDbP10635.
PRIDEP10635.

Protocols and materials databases

StructuralBiologyKnowledgebaseSearch...

Genome annotation databases

EnsemblENST00000359033; ENSP00000351927; ENSG00000100197.
GeneID1565.
KEGGhsa:1565.
UCSCuc003bce.3. human. [P10635-1]
uc003bcf.3. human. [P10635-2]

Organism-specific databases

CTD1565.
GeneCardsGC22M042522.
HGNCHGNC:2625. CYP2D6.
HPAHPA045223.
MIM124030. gene.
608902. phenotype.
neXtProtNX_P10635.
Orphanet240847. Amitriptyline toxicity.
240849. Antipsychotics toxicity.
240865. Clomipramine toxicity.
240867. Codeine toxicity.
240883. Imipramine toxicity.
240893. Nortriptyline toxicity.
240931. Resistance to amitriptyline in the treatment of depression.
240933. Resistance to clomipramine in the treatment of depression.
240939. Resistance to imipramine in the treatment of depression.
240941. Resistance to nortripilline in the treatment of depression.
240947. Resistance to tamoxifene in breast cancer.
240949. Resistance to trimipramine in the treatment of depression.
240951. Resistance to venlafaxine in the treatment of depression.
240957. Susceptibility to adverse reaction due to amitriptyline treatment.
240959. Susceptibility to adverse reaction due to antipsychotics treatment.
240965. Susceptibility to adverse reaction due to clomipramine treatment.
240967. Susceptibility to adverse reaction due to codeine treatment.
240971. Susceptibility to adverse reaction due to imipramine treatment.
240979. Susceptibility to adverse reaction due to nortriptyline treatment.
240987. Susceptibility to adverse reaction due to trimipramine treatment.
240989. Susceptibility to adverse reaction due to venlafaxine treatment.
240915. Trimipramine toxicity.
240919. Venlafaxine toxicity.
PharmGKBPA128.
GenAtlasSearch...

Phylogenomic databases

eggNOGCOG2124.
HOVERGENHBG015789.
KOK17712.
PhylomeDBP10635.
TreeFamTF352043.

Enzyme and pathway databases

ReactomeREACT_111217. Metabolism.
SABIO-RKP10635.

Gene expression databases

BgeeP10635.
CleanExHS_CYP2D6.
GenevestigatorP10635.

Family and domain databases

Gene3D1.10.630.10. 1 hit.
InterProIPR001128. Cyt_P450.
IPR017972. Cyt_P450_CS.
IPR002401. Cyt_P450_E_grp-I.
IPR008069. Cyt_P450_E_grp-I_CYP2D-like.
[Graphical view]
PfamPF00067. p450. 1 hit.
[Graphical view]
PRINTSPR00463. EP450I.
PR01686. EP450ICYP2D.
PR00385. P450.
SUPFAMSSF48264. SSF48264. 1 hit.
PROSITEPS00086. CYTOCHROME_P450. 1 hit.
[Graphical view]
ProtoNetSearch...

Other

EvolutionaryTraceP10635.
GeneWikiCYP2D6.
GenomeRNAi1565.
NextBio6449.
PROP10635.
SOURCESearch...

Entry information

Entry nameCP2D6_HUMAN
AccessionPrimary (citable) accession number: P10635
Secondary accession number(s): Q16752 expand/collapse secondary AC list , Q2XND6, Q2XND7, Q2XNE0, Q6B012, Q6NXU8
Entry history
Integrated into UniProtKB/Swiss-Prot: July 1, 1989
Last sequence update: December 20, 2005
Last modified: April 16, 2014
This is version 158 of the entry and version 2 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
DisclaimerAny medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.

Relevant documents

SIMILARITY comments

Index of protein domains and families

PDB cross-references

Index of Protein Data Bank (PDB) cross-references

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human chromosome 22

Human chromosome 22: entries, gene names and cross-references to MIM